| 2017-04-03 | BIIB | EVP CMO Neuro & Neurodegenerat | Sell | 1,981 | $274.08 | $542,952.48 | -21.9% | → |
| 2017-03-01 | BIIB | EVP CMO Neuro & Neurodegenerat | Sell | 973 | $290.07 | $282,238.11 | -9.7% | → |
| 2016-02-25 | BIIB | EVP CMO Neuro & Neurodegenerat | Sell | 183 | $261.90 | $47,927.70 | -2.2% | → |
| 2016-02-17 | BIIB | EVP CMO Neuro & Neurodegenerat | Sell | 722 | $256.16 | $184,947.52 | -8.3% | → |
| 2016-02-09 | BIIB | EVP CMO Neuro & Neurodegenerat | Sale+OE | 852 | $246.54 | $210,052.08 | -9.9% | → |
| 2015-12-04 | BIIB | EVP CMO Neuro & Neurodegenerat | Sell | 441 | $277.00 | $122,157.00 | -5.4% | → |
| 2015-03-27 | BIIB | Grp SVP, Chief Medical Officer | Sell | 430 | $430.12 | $184,951.60 | -4.8% | → |
| 2015-03-02 | BIIB | Grp SVP, Chief Medical Officer | Sell | 3,174 | $409.49 | $1,299,714.73 | -5.7% | → |
| 2015-02-17 | BIIB | Grp SVP, Chief Medical Officer | Sell | 418 | $389.11 | $162,647.98 | -2.7% | → |